Short answer
Incyte (INCY) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 results for quarter ended September 30, 2026.
Incyte 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.56B and net sales $1.32B, each up 14% YoY, confirming broad commercial momentum
- Core growth accelerating beyond Jakafi: Opzelura sales $255M, up 36%, while Hematology and Oncology sales rose 38% to $235M
- GAAP net loss $785M and diluted EPS $(3.86), driven by $1.23B Vega acquisition IPR&D charge, obscuring underlying operating performance
- 2026 guidance raised: total net sales $5.21B-$5.30B, Opzelura $1.10B-$1.12B, Hematology and Oncology $890M-$910M
- Vega acquisition adds late-stage latarcibart, costing $1.25B upfront with up to $750M in sales milestones and Phase 3 data expected in early 2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Incyte 8-K filings
Get the next INCY 8-K as it lands
Follow INCY for push alerts, or ask the research agent what this filing means.